Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7052MR)

This product GTTS-WQ7052MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7052MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10139MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ6359MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ9482MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ5872MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ12475MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ9861MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ110MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ6532MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW